Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.40 |
| ▸ | ACHE | P22303 | 2/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3087633 | 0.78 | KDM4E (0.44) | KDM4EHDAC8ACHEBCHENPC1 | |
| SCHEMBL11004432 | 0.77 | KDM4E (0.43) | KDM4EHDAC8ACHEBCHENPC1 | |
| SCHEMBL2778719 | 0.75 | KDM4E (0.42) | KDM4EHDAC8ACHEBCHENPC1 | |
| SCHEMBL11286540 | 0.75 | KDM4E (0.42) | KDM4EHDAC8ACHEBCHENPC1 | |
| SCHEMBL721593 | 0.75 | HDAC8 (0.50) | KDM4EHDAC8ACHEBCHENPC1 | |
| SCHEMBL11004427 | 0.75 | KDM4E (0.46) | KDM4EHDAC8ACHEBCHENPC1 | |
| SCHEMBL1055898 | 0.75 | SMN1; SMN2 (0.52) | KDM4EHDAC8ACHEBCHENPC1 | |
| SCHEMBL950597 | 0.75 | KDM4E (0.42) | KDM4EHDAC8ACHEBCHENPC1 | |
| Hydrochloric Acid SCHEMBL1533049 | 0.73 | HDAC8 (0.48) | KDM4EHDAC8ACHEBCHENPC1 | |
| Iodide SCHEMBL4396612 | 0.73 | HDAC8 (0.48) | KDM4EHDAC8ACHEBCHENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8352193-B2 | Methods for deriving a cumulative ranking | TARGET DISCOVERY, INC. (US) | 2013-01-08 | — | — | US | disclosed |
| EP-2479578-A1 | Mass defect labeling for the determination of oligomer sequences | Target Discovery, Inc. (US) | 2012-07-25 | — | — | EP | disclosed |
| EP-1824516-A4 | GLYCAN ANALYSIS USING DEUTERATED GLUCOSE | TARGET DISCOVERY INC (US) | 2008-11-05 | — | — | EP | disclosed |
| US-7316931-B2 | Mass defect labeling for the determination of oligomer sequences | TARGET DISCOVERY, INC. (US) | 2008-01-08 | — | — | US | disclosed |
| EP-1824516-A2 | GLYCAN ANALYSIS USING DEUTERATED GLUCOSE | Target Discovery, Inc. (US) | 2007-08-29 | — | — | EP | disclosed |
| US-20070154900-A1 | Methods for determining protein and peptide terminal sequences | TARGET DISCOVERY, INC (US) | 2007-07-05 | — | — | US | disclosed |
| US-20060120961-A1 | Glycan analysis using deuterated glucose | TARGET DISCOVERY, INC. (US) | 2006-06-08 | — | — | US | disclosed |
| WO-2006050130-A2 | GLYCAN ANALYSIS USING DEUTERATED GLUCOSE | TARGET DISCOVERY, INC. (US) | 2006-05-11 | — | — | WO | disclosed |
| US-20060073485-A1 | Mass defect labeling for the determination of oligomer sequences | TAGET DISCOVERY, INC. (US) | 2006-04-06 | — | — | US | disclosed |
| US-6962818-B2 | Mass defect labeling for the determination of oligomer sequences | TARGET DISCOVERY (US) | 2005-11-08 | — | — | US | disclosed |
| US-20040209251-A1 | Methods for determining protein and peptide terminal sequences | TARGET DISCOVERY, INC. | 2004-10-21 | — | — | US | disclosed |
| EP-1430436-A2 | METHODS FOR DETERMINING PROTEIN AND PEPTIDE TERMINAL SEQUENCES | Target Discovery, Inc. (US) | 2004-06-23 | — | — | EP | disclosed |
| EP-1358458-A2 | MASS DEFECT LABELING FOR THE DETERMINATION OF OLIGOMER SEQUENCES | Target Discovery, Inc. (US) | 2003-11-05 | — | — | EP | disclosed |
| US-20020172961-A1 | Mass defect labeling for the determination of oligomer sequences | TARGET DISCOVERY (US) | 2002-11-21 | — | — | US | disclosed |
| WO-2002066952-A2 | MASS DEFECT LABELING FOR THE DETERMINATION OF OLIGOMER SEQUENCES | TARGET DISCOVERY, INC (US) | 2002-08-29 | — | — | WO | disclosed |
| WO-2002061661-A2 | METHODS FOR DETERMINING PROTEIN AND PEPTIDE TERMINAL SEQUENCES | TARGET DISCOVERY, INC. (US) | 2002-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060120961-A1 | Glycan analysis using deuterated glucose | UGGT1, GALE, FUT6 | KDM4E 4343/4885HDAC8 1398/4885ACHE 3671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.